North American Cystic Fibrosis Conference 27 October Noreen R Henig, MD Chief Development Officer ProQR Therapeutics
|
|
- Thomasine Hunt
- 5 years ago
- Views:
Transcription
1 Proof of Concept Study to Demonstrate the Effects of QR-010 on Nasal Potential Difference in Subjects With Cystic Fibrosis with the F508del CFTR Mutation Noreen R Henig, MD Chief Development Officer ProQR Therapeutics North American Cystic Fibrosis Conference 27 October 2016
2 QR-010 for F508del cystic fibrosis RNA DNA CFTR QR-010 Single stranded 33-mer RNA oligonucleotide Chemically modified for stability and uptake Designed to target F508del mutation c Formulated in saline solution Inhaled delivery for efficient lung delivery and systemic uptake Phase 1b Safety and Tolerability study in homozygous F508del Proof-of-concept NPD study ProQR Therapeutics NACFC
3 Nasal Potential Difference is direct measurement of CFTR function Sodium Chloride ENaC Protein CFTR Protein NPD is the only direct in vivo measurement capable of separating sodium and chloride transport Down regulator NPD has been used as an important endpoint in clinical trials evaluating therapeutic agents ProQR Therapeutics NACFC
4 Study Design Open-label NPD study in F508del CF subjects Screening NPD Baseline NPD & Nasal Sample Day 15 NPD Day 26 (EOT) NPD & Nasal Sample End of Study NPD 14 Day SCREENING 28 Day TREATMENT PERIOD 21 Day FOLLOW-UP = Dose Administered 8 homozygous and 8 compound heterozygous (allcomers) subjects >18 years old Multiple dose design: 12 doses (3 per week x 4 weeks) Intranasal administration Endpoints: CFTR-mediated total chloride transport (primary) Other NPD parameters Safety, SNOT-22 and NERS assessments Sweat test (Day 1, 15, 26, 47) 5 expert participating sites in EU (CTN) and US (TDN) ProQR Therapeutics NACFC
5 Subject Eligibility Inclusion Criteria Nasal potential difference (NPD) measurement at screening consistent with CF (> mv) Confirmed diagnosis of CF (sweat chloride > 60 mmol/l) Confirmation of CFTR gene F508del mutations (homozygous or compound heterozygous) Stable lung function Exclusion Criteria Use of lumacaftor and/or ivacaftor Acute allergy or infection affecting nasal conditions not resolved within 14 days prior screening Use of any investigational drug or device Hemoptysis Breast-feeding or pregnant ppfev 1 40% Body mass index 18 kg/m 2 ProQR Therapeutics NACFC
6 Study Conduct 10 subjects F508del/F508del were enrolled in cohort 1 There were no discontinuations All subjects received all 12 doses 8 subjects were enrolled in the F508del heterozygous cohort 2 There were no discontinuations 7 subjects received all 12 doses; 1 subject missed 1 dose due to AE (malaise) NPD tests Standardized SOP with centralized solutions have been used All tracings have been read and scored by a blinded central reader Data was analysed including subjects meeting NPD parameters at baseline within the range as defined by the TDN-CCD of >-6.6 mv ProQR Therapeutics NACFC
7 Subject Demographics Characteristic F508del / F508del Mean ± SD (N=10) F508del Heterozygous Mean ± SD (N=8) Age, years 25.8 ± ± 15.8 Sex, n (%) Male Female 6 (60%) 4 (40%) 4 (50.0%) 4 (50.0%) Race, n (%) Caucasian 10 (100%) 8 (100.0%) BMI (kg/m 2 ) 22.8 ± ± 3.3 Predicted FEV1 (%) 74.2 ± ± 16.9 Sweat Chloride (mmol/l) 98.7 ± ± 18.0 Baseline Cl-Free+Iso (mv) -1.2 ± ± 5.9 Baseline SNOT-22 Total Score 14.9 ± ± 17.7 ProQR Therapeutics NACFC
8 Preliminary Safety & Tolerability Data Pooled cohort data (N=18) No SAE reported AEs reported included nausea, fatigue, headache and cough No change in SNOT-22 and NERS QR-010 was safe and well tolerated during the study ProQR Therapeutics NACFC
9 PQ Top-Line NPD Results ProQR Therapeutics NACFC
10 CFTR-Mediated Total Chloride Transport Change from baseline in F508del/F508del Subjects N = 7 (per protocol population) Parameter = within subject change from baseline in Cl-free+iso Average both nostrils Baseline = average of 2 most recent pre-dose assessments p = one-sided 5% paired t-test ProQR Therapeutics NACFC
11 CFTR Mediated Sodium Down-Regulation Change in Max Basal PD Parameter in F508del/F508del Subjects N = 7 (per protocol population) Parameter = within subject change from baseline in max basal PD Average both nostrils Baseline = average of 2 most recent pre-dose assessments p = one-sided 5% paired t-test ProQR Therapeutics NACFC
12 CFTR-Mediated Total Chloride and Down-Regulated Sodium Transport Comparison of analysis methods in F508del/F508del Subjects N = 7 Baseline defined by average of 2 most recent pre-dose assessments ProQR Therapeutics NACFC
13 CFTR-Mediated Total Chloride Transport Change from Baseline in F508del Heterozygous Subjects Functional Class I II V Mutation Q493X G>A Y1092X G>A N1303K I336K G>A N = 7 (per protocol population) Parameter = within subject change from baseline in Cl-free+iso Average both nostrils Baseline = average of 2 most recent pre-dose assessments p = one-sided 5% paired t-test ProQR Therapeutics NACFC
14 QR-010 Improves CFTR Function Proof-of-concept has been established for QR-010 QR-010 significantly improved CFTR function in F508del/F508del subjects Supported by NPD sensitivity analyses Positive change in sodium transport (max basal PD) QR-010 did not improve CFTR function in F508del heterozygous subjects Further data analysis ongoing Preclinical work being considered to better understand the impact of the second allele NPD effect size comparable to other CF approved therapies ProQR Therapeutics NACFC
15 Acknowledgments Isabelle Sermet-Gaudelus, MD, PhD JP Clancy, MD Christiane de Boeck, MD, PhD The QR-010 project has received funding from the European Union s Horizon 2020 research and innovation programme under grant agreement No David Nichols, MD Jerry Nick, MD Stuart Elborn, Marcus Mall and Jim Bolognese for ADRC guidance George Solomon, MD Steve Rowe and Bo Liu for NPD central reading ProQR Therapeutics NACFC
North American Cystic Fibrosis Conference 27 October Noreen R Henig, MD Chief Development Officer ProQR Therapeutics
Proof of Concept Study to Demonstrate the Effects of QR-010 on Nasal Potential Difference in Subjects With Cystic Fibrosis with the F508del CFTR Mutation Noreen R Henig, MD Chief Development Officer ProQR
More informationANALYST & INVESTOR EVENT NACFC 2016, Orlando, Florida
ANALYST & INVESTOR EVENT NACFC 216, Orlando, Florida Date: October 27th, 216 Presenters: Daniel de Boer, Noreen Henig and JP Clancy Agenda Overview and introduction by Daniel de Boer The relevance of the
More informationTransformational Treatments. PRESTON W. CAMPBELL, III, M.D. Executive Vice President for Medical Affairs
Transformational Treatments PRESTON W. CAMPBELL, III, M.D. Executive Vice President for Medical Affairs Symptom-based CF Therapies 45 Median Predicted Survival Age of US Patients with Cystic Fibrosis 41
More informationPhase 3 EVOLVE & EXPAND Studies of Tezacaftor/Ivacaftor Combination Show Statistically Significant Improvements in Lung Function and Other Measures
Phase 3 EVOLVE & EXPAND Studies of Tezacaftor/Ivacaftor Combination Show Statistically Significant Improvements in Lung Function and Other Measures in CF Patients March 29, 2017 Agenda Introduction Michael
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Moss RB, Flume PA, Elborn JS, et al, on behalf
More informationPhase 1 and 2 Data for Triple Combination Regimens Demonstrate Improvements in Lung Function and Other Measures in CF Patients
Phase 1 and 2 Data for Triple Combination Regimens Demonstrate Improvements in Lung Function and Other Measures in CF Patients July 18, 2017 Agenda Introduction Michael Partridge, VP Investor Relations
More informationNACFC investor meeting. Dr Katja Conrath, Therapeutic Head CF Dr Piet Wigerinck, CSO NACFC November 2017 Copyright 2017 Galapagos NV
NACFC investor meeting Dr Katja Conrath, Therapeutic Head CF Dr Piet Wigerinck, CSO NACFC 2017 2 November 2017 Copyright 2017 Galapagos NV Disclaimer This presentation contains forward-looking statements,
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION LUMACAFTOR / IVACAFTOR (Orkambi Vertex Pharmaceuticals [Canada] Inc.) Indication: Cystic Fibrosis, F508del-CFTR mutation Recommendation: The CADTH
More informationCavosonstat Phase 2 Trial Results. November 28 th, 2016
Phase 2 Trial Results November 28 th, 2016 Nivalis Therapeutics 2016 Agenda Introduction Mike Carruthers, Chief Financial Officer Initial Remarks Jon Congleton, President and CEO Data Highlights David
More information"Management and Treatment of Patients with Cystic fibrosis (CF)
"Management and Treatment of Patients with Cystic fibrosis (CF) Dr. Malena Cohen-Cymberknoh Pediatric Pulmonology and CF Center Hadassah Hebrew-University Medical Center Jerusalem, Israel Afula, March
More informationWe strive to develop innovative solutions that improve and extend the lives of people with cystic fibrosis
Nivalis Therapeutics, Inc., October 2015 Analyst Breakfast at NACFC We strive to develop innovative solutions that improve and extend the lives of people with cystic fibrosis Disclaimer Regarding Forward
More informationPA Update: Oral Cystic Fibrosis Modulators
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationGLPG1837 in Subjects with Cystic Fibrosis (CF) and the G551D Mutation: results from a Phase II study (SAPHIRA1)
GLPG1837 in Subjects with Cystic Fibrosis (CF) and the G551D Mutation: results from a Phase II study (SAPHIRA1) ECFS, Sevilla, Spain 9 June 2017 Jane Davies on behalf of the SAPHIRA1 Study Team Copyright
More informationOral Cystic Fibrosis Modulators
Oral Cystic Fibrosis Modulators Goals: To ensure appropriate drug use and limit to patient populations in which they have demonstrated to be effective and safe. To monitor for clinical response for appropriate
More informationThe Future of CF Therapy
The Future of CF Therapy Peter J. Mogayzel, Jr., M.D., Ph.D. Eudowood Division of Pediatric Respiratory Sciences The Johns Hopkins School of Medicine Overview The Future of CF Therapy Personalized therapy
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Cystic Fibrosis Transmembrane Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Prime Therapeutics
More informationImproved repeatability of nasal potential difference with a larger surface catheter
Journal of Cystic Fibrosis 14 (2015) 317 323 www.elsevier.com/locate/jcf Original Article Improved repeatability of nasal potential difference with a larger surface catheter François Vermeulen, Marijke
More informationEnabling CF Therapeutic Development
Enabling CF Therapeutic Development PRESTON W. CAMPBELL, III, M.D. Executive Vice President for Medical Affairs No Disclosures Cystic Fibrosis In 1955 In 1955 most children with CF did not live long enough
More informationTHE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF)
THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF) Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210. Vertex and the Vertex triangle logo are registered trademarks for Vertex
More informationBriefing Document. FDA Pulmonary - Allergy Drugs Advisory Committee
FDA Advisory Committee Briefing Materials Page 1 of 157 Briefing Document FDA Pulmonary - Allergy Drugs Advisory Committee Ivacaftor for the Treatment of Cystic Fibrosis in Patients Age 6 Years and Older
More informationOrkambi. Orkambi (lumacaftor/ivacaftor) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.06 Subject: Orkambi Page: 1 of 6 Last Review Date: November 30, 2018 Orkambi Description Orkambi (lumacaftor/ivacaftor)
More informationClass Update with New Drug Evaluation: Oral Cystic Fibrosis Modulators
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationA Genetic Approach to the Treatment of Cystic Fibrosis
A Genetic Approach to the Treatment of Cystic Fibrosis Peter Mueller, PhD Chief Scientific Officer and Executive Vice President Global Research and Development Vertex Pharmaceuticals, Incorporated March
More informationPharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor as a Therapy for Cystic Fibrosis
Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor as a Therapy for Cystic Fibrosis Federico Goodsaid Vice President Strategic Regulatory Intelligence Vertex Pharmaceuticals Is there
More informationHIT-CF New clinical trial design in Cystic Fibrosis
HIT-CF New clinical trial design in Cystic Fibrosis Peter van Mourik, MD, PhD-student Pediatric Pulmonology, University Medical Center Utrecht, the Netherlands Contents - Difficulties of clinical trials
More informationBrand Name: Kalydeco. Generic: ivacaftor. Manufacturer 1 : Vertex Pharmaceuticals Incorporated
Brand Name: Kalydeco Generic: ivacaftor Manufacturer 1 : Vertex Pharmaceuticals Incorporated Drug Class 2,3 : Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Potentiator Uses: Labeled Uses 1,2,3,4,5
More informationCystic fibrosis (CF) is the most frequent. Ivacaftor treatment in patients with cystic REVIEW. Isabelle Sermet-Gaudelus
Eur Respir Rev 2013; 22: 127, 66 71 DOI: 10.1183/09059180.00008512 CopyrightßERS 2013 REVIEW Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation Isabelle Sermet-Gaudelus ABSTRACT:
More informationCystic Fibrosis Foundation Patient Registry 2013
5/9/2015 Targeting CFTR to Treat Cystic Fibrosis: Small Molecule Therapy Mary Ellen Kleinhenz, MD Director, UCSF Adult Cystic Fibrosis Program Professor of Medicine UCSF Division of Pulmonary, Critical
More informationCystic Fibrosis the future
Cystic Fibrosis the future Pathophysiologic cascade Abnormal Gene Abnormal CFTR Therapy Gene replacement Protein replacement Gene read through therapy Abnormal sodium chloride & water movement through
More informationCost-effectiveness of Ivacaftor (Kalydeco ) for the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation
Cost-effectiveness of Ivacaftor (Kalydeco ) for the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation January 2013 1. A rapid review submission on the drug ivacaftor
More informationSymdeko. Symdeko (tezacaftor and ivacaftor) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.10 Subject: Symdeko Page: 1 of 5 Last Review Date: June 22, 2018 Symdeko Description Symdeko (tezacaftor
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Cystic Fibrosis Transmembrane Page 1 of 11 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Prime Therapeutics
More informationKalydeco. Kalydeco (ivacaftor) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.03 Subject: Kalydeco Page: 1 of 6 Last Review Date: November 30, 2018 Kalydeco Description Kalydeco
More informationTargeted therapies to improve CFTR function in cystic fibrosis
Brodlie et al. Genome Medicine (2015) 7:101 DOI 10.1186/s13073-015-0223-6 REVIEW Targeted therapies to improve CFTR function in cystic fibrosis Malcolm Brodlie 1*, Iram J. Haq 2, Katie Roberts 2 and J.
More informationOpening Doors to CF Clinical Research: Change is Coming
Opening Doors to CF Clinical Research: Change is Coming Disclosures Contracts with sponsors for clinical trials conducted at UNC-Chapel Hill: CFFT NIH/NHLBI AbbVie Inc. Aptalis Pharma US, Inc. Janssen
More informationClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: October 3, ClinicalTrials.gov ID: NCT
ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: October 3, 2012 ClinicalTrials.gov ID: NCT00457821 Study Identification Unique Protocol ID: VX06-770-101 Brief Title:
More informationCystic Fibrosis: Progress in Treatment Management. Patrick A. Flume, M.D. Medical University of South Carolina
Cystic Fibrosis: Progress in Treatment Management Patrick A. Flume, M.D. Medical University of South Carolina Disclosures Grant support Mpex Pharmaceuticals, Inc Gilead Sciences, Inc Bayer Healthcare AG
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Wells JM, Farris RF, Gosdin TA, et al. Pulmonary
More informationCystic Fibrosis Diagnosis and Treatment
Cystic Fibrosis Diagnosis and Treatment Financial Disclosures Personal financial relationships with commercial interests relevant to medicine, within the past 3 years: NJH site PI for AstraZeneca. As faculty
More informationNew Drug Evaluation: Lumacaftor/Ivacaftor
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-77 in persons
More informationRespiratory Pharmacology: Treatment of Cystic Fibrosis
Respiratory Pharmacology: Treatment of Cystic Fibrosis Dr. Tillie-Louise Hackett Department of Anesthesiology, Pharmacology and Therapeutics University of British Columbia Associate Head, Centre of Heart
More informationCF: Understanding the Biology Curing the Disease
CF: Understanding the Biology Curing the Disease Scott H. Donaldson, MD Associate Professor of Medicine Director, Adult CF Care Center University of North Carolina at Chapel Hill Defining the path Drilling
More informationCYSTIC FIBROSIS OBJECTIVES NO CONFLICT OF INTEREST TO DISCLOSE
CYSTIC FIBROSIS Madhu Pendurthi MD MPH Staff Physician, Mercy Hospital Springfield, MO NO CONFLICT OF INTEREST TO DISCLOSE OBJECTIVES Epidemiology of Cystic Fibrosis (CF) Genetic basis and pathophysiology
More informationExploring New Advances and Best Practices to Personalize Therapy and Improve Lung Function in Cystic Fibrosis
CME/CNE/CPE Exploring New Advances and Best Practices to Personalize Therapy and Improve Lung Function in Cystic Fibrosis Course Director Jerry Nick, MD National Jewish Health University of Colorado Denver,
More informationEfficacy of NaCl nebulized hypertonic solutions in cystic fibrosis
Acta Biomed 2014; Vol. 85, Supplement 4: 10-18 Mattioli 1885 Original article Efficacy of NaCl nebulized hypertonic solutions in cystic fibrosis Azienda Ospedaliero Universitaria Policlinico, DAI Scienze
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAt-A-Glance report 2014
At-A-Glance report 14 Cystic Fibrosis in Europe Facts and Figures 14 The European Cystic Fibrosis Society Patient Registry (ECFSPR) is happy to present this report with key information about how cystic
More informationAt-A-Glance report 2013
At-A-Glance report 213 Cystic Fibrosis in Europe Facts and Figures 213 The European Cystic Fibrosis Society Patient Registry (ECFSPR) is happy to present this report with key information about how cystic
More informationivacaftor 150mg film-coated tablets (Kalydeco ) SMC No. (1193/16) Vertex Pharmaceuticals (Europe) Ltd
ivacaftor 150mg film-coated tablets (Kalydeco ) SMC No. (1193/16) Vertex Pharmaceuticals (Europe) Ltd 04 November 2016 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationCYSTIC FIBROSIS CANADA S CF PHYSICIAN PANEL ON LUMACAFTOR/IVACAFTOR: RECOMMENDATIONS FOR CRITERIA FOR CLINICAL USE
CYSTIC FIBROSIS CANADA S CF PHYSICIAN PANEL ON LUMACAFTOR/IVACAFTOR: RECOMMENDATIONS FOR CRITERIA FOR CLINICAL USE I - INTRODUCTION a) Cystic Fibrosis Cystic fibrosis (CF) is the most common fatal genetic
More informationMolecular Basis of Personalized Therapies for CF: Can We Treat All Patients?
CF Europe Meeting Molecular Basis of Personalized Therapies for CF: Can We Treat All Patients? Margarida D Amaral Brussels, 13 June 2015 The CF Pathogenesis Cascade 2 Defective CF Genes Deficient CFTR
More informationCase Study What is the Relationship Between the Cell Membrane and Cystic Fibrosis?
Names: Date: Case Study What is the Relationship Between the Cell Membrane and Cystic Fibrosis? Dr. Weyland examined a six month old infant that had been admitted to University Hospital earlier in the
More informationCorporate Presentation
Corporate Presentation Developing Innovative Therapies for Patients Suffering from Life-threatening Diseases NASDAQ: LJPC September 2016 Forward-Looking Statements These slides contain "forward-looking"
More informationBTIG LLC Dane Leone, CFA (212) Source: SAPHIRA 1 Results (December 20th 2016), Ph2a open label trial of GLPG1837
Pre-clinical assay outcomes at Vertex have proven to be reliable markers for in vivo results, we expect the same from Galapagos: Outcomes from the EVOLVE and EXPAND studies have set a new bar for clinical
More informationOpinion 7 November 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 7 November 2012 KALYDECO 150 mg film-coated tablets B/56 (CIP code: 34009 266 060 5 3) Applicant: VERTEX INN ATC Code
More informationALN-PCSsc, an RNAi Investigational Agent That Inhibits PCSK9 Synthesis With the Potential for Effective Bi-Annual Dosing: Interim Results
ALN-PCSsc, an RNAi Investigational Agent That Inhibits PCSK9 Synthesis With the Potential for Effective Bi-Annual Dosing: Interim Results Kevin Fitzgerald, PhD Co-authors: Amy Simon 1, Suellen White 1,
More informationAnti-inflammatory Therapy Targets Orphan Lung Disease-June 17
Anti-inflammatory Therapy Targets Orphan Lung Disease-June 17 Disease Modification in Cystic Fibrosis (CF) Targeted Approach in Pulmonary Hypertension (PH) Experienced Management Team Greg Duncan President/CEO
More informationTHE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF)
THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF) Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210. Vertex and the Vertex triangle logo are registered trademarks of Vertex
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationA Case of Cystic Fibrosis
Name(s) Date A Case of Cystic Fibrosis Dr. Weyland examined a six month old infant that had been admitted to University Hospital earlier in the day. The baby's parents had brought young Zoey to the emergency
More informationClass Update: Oral Cystic Fibrosis Modulators
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More information12th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) 28 September 2016
A Randomized, Single-Blind, Placebo-Controlled, Phase /2 Study of ALN-AAT, an Investigational RNAi Therapeutic for the Treatment of Alpha- Antitrypsin Deficiency Associated Liver Disease: Interim Study
More informationYou Can Observe a Lot By Just Watching. Wayne J. Morgan, MD, CM
You Can Observe a Lot By Just Watching Wayne J. Morgan, MD, CM Disclosures Genentech Epidemiological Study of Cystic Fibrosis, Scientific Advisory Group CF Foundation Data Safety Monitoring Board Registry/Comparative
More informationABC/3TC/ZDV ABC PBO/3TC/ZDV
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationInitiation Guide. Images not actual size.
Initiation Guide Images not actual size. INDICATIONS AND USAGE SYMDEKO is indicated for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation
More informationNew Zealand Datasheet
New Zealand Datasheet KALYDECO (ivacaftor) NAME OF THE MEDICINE Ivacaftor is N-(2,4-di-tert-butyl-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide. The empirical formula of ivacaftor is C 24 H
More informationCompound heterozygosity Yurii S. Aulchenko yurii [dot] aulchenko [at] gmail [dot] com. Thursday, April 11, 13
Compound heterozygosity Yurii S. Aulchenko yurii [dot] aulchenko [at] gmail [dot] com 1 Outline Recessive model Examples of Compound Heterozygosity Compound Double Heterozygosity (CDH) test 2 Recessive
More informationPART VI Summary of the RMP
PART VI Summary of the RMP Summary of Risk Management Plan for ORKAMBI This is a summary of the risk management plan (RMP) for ORKAMBI. The RMP details important risks of ORKAMBI, how these risks can be
More informationA randomized placebo-controlled trial of miglustat in cystic fibrosis based on nasal potential difference
Journal of Cystic Fibrosis 11 (2012) 231 236 www.elsevier.com/locate/jcf Original Article A randomized placebo-controlled trial of miglustat in cystic fibrosis based on nasal potential difference Anissa
More informationCystic fibrosis and survival to 40 years: a study of cystic fibrosis transmembrane conductance regulator function
Eur Respir J 2011; 37: 1076 1082 DOI: 10.1183/09031936.00079010 CopyrightßERS 2011 Cystic fibrosis and survival to 40 years: a study of cystic fibrosis transmembrane conductance regulator function N.J.
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSYNOPSIS. Drug substance(s) Budesonide/formoterol Document No. Edition No. Study code SD Date 16 December 2004
Drug product SYMBICORT pmdi 160/4.5 µg SYNOPSIS Drug substance(s) Budesonide/formoterol Document No. Edition No. Date 16 December 2004 A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled
More informationPediatrics Grand Rounds 18 Sept University of Texas Health Science Center. + Disclosure. + Learning Objectives.
Disclosure Dr Donna Willey Courand receives research support from Cystic Fibrosis Therapeutics The Cystic Fibrosis Foundation Children with Special Health Care Needs Cystic Fibrosis 05: Improving Survival
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance
More information(<40 and 40) and screening ppfev 1. , were done for patients with baseline ppfev 1
Efficacy and safety of lumacaftor/ivacaftor combinion therapy in pients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis J Stuart Elborn, Bonnie W Ramsey,
More informationA treatment option for patients with CF who have responsive mutations
A treatment option for patients with CF who have responsive mutations INDICATIONS AND USAGE SYMDEKO is indicated for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are
More informationSponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study
More informationHuman Genetic Disorders
Human Genetic Disorders HOMOLOGOUS CHROMOSOMES Human somatic cells have 23 pairs of homologous chromosomes 23 are inherited from the mother and 23 from the father HOMOLOGOUS CHROMOSOMES Autosomes o Are
More informationQ1 Results 2018 Webcast presentation 26 April 2018
Q1 Results 2018 Webcast presentation 26 April 2018 Disclaimer This presentation contains forward-looking statements, including (without limitation) statements concerning the progress of our clinical pipeline,
More informationSYNOPSIS. Study center(s) This study was conducted in the United States (128 centers).
Drug product: Drug substance(s): Document No.: Edition No.: Study code: Date: SYMBICORT pmdi 160/4.5 µg Budesonide/formoterol SD-039-0725 17 February 2005 SYNOPSIS A Twelve-Week, Randomized, Double-blind,
More informationC.S. HAWORTH 1, A. WANNER 2, J. FROEHLICH 3, T. O'NEAL 3, A. DAVIS 4, I. GONDA 3, A. O'DONNELL 5
Inhaled Liposomal Ciprofloxacin in Patients With Non-Cystic Fibrosis Bronchiectasis and Chronic Pseudomonas aeruginosa: Results From Two Parallel Phase III Trials (ORBIT-3 and -4) C.S. HAWORTH 1, A. WANNER
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationThis was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCystic Fibrosis: KOL Insight [2017]
Cystic Fibrosis: KOL Insight [2017] Cystic Fibrosis: KOL Insight [2017] BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio
More informationNovartis Vaccines and Diagnostics S.r.l.
27NOV15 Page 1 of 11 Sponsor: Investigational Product: Novartis Vaccines and Diagnostics S.r.l., Adjuvanted trivalent influenza virus vaccine (surface antigen, inactivated, adjuvanted with MF59C.1, egg-derived)
More informationCystic Fibrosis. Jennifer McDaniel, BS, RRT-NPS
Cystic Fibrosis Jennifer McDaniel, BS, RRT-NPS Overview Cystic fibrosis is the most common fatal, inherited disease in the U. S. CF results from a defective autosomal recessive gene One copy of gene =
More informationCystic Fibrosis Care at the University of Florida
Cystic Fibrosis Care at the University of Florida Objectives To introduce you to the University of Florida CF Center To review center specific data for the UF pediatric CF Center To review current status
More informationTHE JOURNAL OF PEDIATRICS
SUPPLEMENT www.jpeds.com THE JOURNAL OF PEDIATRICS Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation Philip M. Farrell, MD, PhD 1, Terry B. White, PhD 2, Clement L.
More informationSYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20 mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGlecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2
Phase 3 Treatment Naïve or Experienced Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2 *ENDURANCE-2: Study Features ENDURANCE-2 Trial Design: Randomized, double-blind, placebo-controlled
More informationNew and Novel Medications for Respiratory Care
New and Novel Medications for Respiratory Care JASON MOORE, PHARM.D. BCCCP CLINICAL STAFF PHARMACIST STORMONT-VAIL HEALTH Objectives Quick overview of the newest FDA-approved repiratory-related medications
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION KALYDECO. Ivacaftor tablets 150 mg Ivacaftor granules 50 mg per packet, 75 mg per packet
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr KALYDECO Ivacaftor tablets 150 mg Ivacaftor granules 50 mg per packet, 75 mg per packet Cystic Fibrosis Transmembrane Conductance Regulator
More informationClinical Trials for Rare Diseases in CDER
Clinical Trials for Rare Diseases in CDER CDER Antibacterial Task Force/CTTI Think Tank October 11, 2012 Kathryn O Connell, MD PhD Medical Officer, Rare Diseases Program Office of New Drugs, CDER, FDA
More informationHOW DISEASE ALTERING THERAPY IS CHANGING THE GOALS OF TREATMENT IN CF
HOW DISEASE ALTERING THERAPY IS CHANGING THE GOALS OF TREATMENT IN CF Peter D. Sly MBBS, MD, FRACP, DSc OUTLINE Goals of CF treatment Drivers of early disease neutrophilic inflammation oxidative stress
More informationKevin Fitzgerald, PhD
A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-PCSsc), Targeting PCSK9 for the Treatment of Hypercholesterolemia: Initial Phase 1 Study Results Kevin Fitzgerald, PhD Co-authors: Amy
More informationGET TO KNOW ORKAMBI. WHAT IS ORKAMBI (lumacaftor/ivacaftor)? IMPORTANT SAFETY INFORMATION
Kristi, Sydney s mom Sydney, Age 4 years, F508del/ F508del GET TO KNOW ORKAMBI A resource for caregivers of children age 2 through 5 years with 2 copies of the F508del-CFTR mutation WHAT IS ORKAMBI (lumacaftor/ivacaftor)?
More information